ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...
FAYETTEVILLE, GA, UNITED STATES, March 10, 2026 /EINPresswire.com/ -- Chronic diabetic wounds fail to heal because ...
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatm ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
A recent review identifies interleukin-36 (IL-36) as a transformative driver of vascular inflammation, revealing that serum ...
Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 –– Patients dosed in both COMO and ...
A Nasdaq-listed biotechnology company repositioned as a global platform for acquiring and advancing clinical-stage assets. NovaBridge Biosciences is built around two principal programs, givastomig in ...
Leerink Global Healthcare Conference 2026 March 10, 2026 11:20 AM EDTCompany ParticipantsScott Reents - Executive VP & ...
FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...
(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in ...
Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results